Classic Hodgkin Lymphoma – Old Disease, New Directions: An Update on Pathology, Molecular Features and Biological Prognostic Markers

Anamarija M. Perry1, Lauren B. Smith1, Adam Bagg2

1Department of Pathology, University of Michigan, Ann Arbor, MI, USA, 2Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Correspondence: anaperry@med.umich.edu; Tel.: + 734 232 5376; Fax.: + 734 232 5360

Received: 18 January 2021; Accepted: 19 February 2021

Abstract
The aim of this paper is to review morphologic, immunophenotypic, and molecular features of classic Hodgkin lymphoma, as well as different prognostic markers in this neoplasm. Classic Hodgkin lymphoma (CHL) accounts for 15-25% of all lymphomas in the Western world. The hallmark of this disease is the neoplastic Hodgkin/Reed-Sternberg (HRS) cell, which is favored to be derived from germinal center B-cells but has lost many of the B-cell markers. HRS cells are scattered within a dense inflammatory infiltrate, and through a network of cytokines and chemokines they shape their microenvironment, evade immune response, survive, and grow. In the last two decades multiple prognostic markers related to HRS cells, the microenvironment or both, have been evaluated in patients with CHL. They include clinical, immunohistochemical, cytogenetic, and molecular markers that can predict survival and identify high-risk patients who will likely relapse after therapy. More recently, circulating tumor DNA analysis by next-generation sequencing has opened new avenues for diagnosis and disease monitoring after therapy. The increased understanding of molecular mechanisms underlying CHL pathogenesis has led to successful implementation of novel therapies, such as anti-PD-1 antibodies, which are becoming a mainstay of treatment in relapsed/refractory patients. Conclusion. Currently, pathologic prognostic markers are not routinely assessed at initial diagnosis of CHL. However, as more therapies become available, it will be important to identify patients with high-risk disease who may benefit from more intense or targeted therapy upfront.

Key Words: Classic Hodgkin Lymphoma • Prognostic Markers • Immunohistochemical Markers • Tumor Microenvironment • Epstein-Barr Virus.

Introduction
Hodgkin lymphoma is a common lymphoma in the Western world accounting for 15-25% of all lymphomas. This group is comprised of two morphologically and immunophenotypically distinct entities – classic Hodgkin lymphoma (CHL) which accounts for over 90% of cases and nodular lymphocyte predominant Hodgkin lymphoma (1, 2). Although “Hodgkin's disease” was first reported nearly 200 years ago and Hodgkin/Reed-Sternberg (HRS) cells were described at the turn of the 20th century, the nature of this disease (i.e. neoplastic vs. infectious/inflammatory) remained a mystery for a long time (3, 4). The B-cell origin of HRS cells was finally elucidated in the 1990s and the new terminology “Hodgkin lymphoma” was included in the Revised European American Lymphoma (REAL) Classification (5-7). Since then, CHL has been a focus of extensive research which paved the way for better risk stratification and novel therapies.

Classic Hodgkin lymphoma has a bimodal age distribution, with the first peak from 15 to 35 years of age and the second after 55 years of age. In resource-poor countries, however, the first peak occurs earlier in childhood. The overall male-to-female ratio is 1.5:1, but females have higher incidence of nodular sclerosis subtype of CHL (2, 8-10). Clini-
CHL mainly involves lymph nodes, most frequently above the diaphragm with cervical, mediastinal, axillary, and supraclavicular lymph node chains being most commonly affected. In a subset of patients, extranodal tissues are involved, such as spleen, lungs and liver (2, 10). Bone marrow involvement is uncommon, occurring in approximately 5% of patients and is more common in the elderly and HIV positive patients (11). So-called “B-symptoms” such as fever, weight loss and night sweats are seen in 30-40% of patients (10). Modern therapy of CHL is based on risk stratification with a goal of curing the patient while minimizing acute toxicity and long-term complications, the most feared being malignancy such as acute leukemia and myelodysplastic syndrome (12). Imaging studies, specifically fluorodeoxyglucose positive emission tomography (FDG-PET) is used in staging as well as during treatment to assess response to chemotherapy and plan further treatment (13). For early stage CHL, the standard treatment includes ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy with or without involved-field radiation therapy. Even though, compared to many lymphomas, CHL has a very good prognosis and high cure rates, 10-30% of patients will experience relapse and 5-10% are refractory to initial treatment. The management of these patients is challenging and includes high-dose chemotherapy, autologous stem cell transplant, as well as anti-CD30 antibody brentuximab vedotin, and more recently anti-PD-1 antibodies, such as pembrolizumab and nivolumab (12, 14-16).

This review will summarize the most relevant pathologically-determined prognostic markers.

### Histopathologic Characteristics and Immunophenotype

Classic Hodgkin lymphoma is histologically characterized by HRS cell and its variants, that usually comprise less than 1% of cellular infiltrate, scattered in a mixed inflammatory background. Hodgkin/Reed-Sternberg cell has two or multiple nuclei with open chromatin, accentuated nuclear membrane, and prominent eosinophilic nucleoli. Morphologic variants of HRS cells include mononuclear Hodgkin cells, degenerated mummified cells and lacunar cells, which show shrinkage artifact (i.e. lacunae) in the formalin-fixed tissue. WHO classification recognized four morphologically distinct subtypes of CHL – nodular sclerosis (50-80% of cases), mixed cellularity (20-30% of cases), lymphocyte-rich (5% of cases), and lymphocyte-depleted (1% of cases). These subtypes are associated with different clini-
cal presentations and are differently represented among varied age groups (2, 10).

Nodular sclerosis CHL, the most common subtype in the Western world, typically presents as a mediastinal mass in young adults. Histologically, lymph nodes show nodular pattern of effacement with cellular nodules surrounded by thick fibrotic bands. The infiltrate is composed of scattered lacunar cells (as well as other HRS variants), which sometimes form clusters and sheets, in a mixed inflammatory background composed of small lymphocytes, plasma cells, histiocytes, eosinophils, and neutrophils (Figure 1A and 1B). Mixed cellularity CHL is more commonly seen in the elderly population, among patients with HIV infection, as well as in the pediatric population in developing countries. Notably, around 75% of cases are associated with Epstein-Barr virus (EBV). Histologically, lymph node shows diffuse effacement by infiltrate composed of scattered HRS cells in an inflammatory background (Figure 1C and 1D). Lymphocyte-rich subtype is relatively rare and patients frequently present in early clinical stages. Lymph node is effaced in nodular, or less frequently diffuse pattern, and HRS cells are seen in a background composed mainly of small lymphocytes, hence the term "lymphocyte-rich". In the nodular pattern, small/regressed germinal centers are usually seen in the nodules with HRS cells/variants in the expanded mantle zones (Figure 1E and 1F). Lymphocyte-depleted subtype, the rarest of all, is associated with aggressive clinical behavior, and often with HIV infection. Histologically, it is characterized by sheets of neoplastic cells, sometimes with prominent fibrosis, with scarce inflammatory cells in the background (2, 20).

### Table 1. Immunohistochemical Profile of Classic Hodgkin Lymphoma

<table>
<thead>
<tr>
<th>Positive markers</th>
<th>Negative or rarely positive markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD30</td>
<td>CD19</td>
</tr>
<tr>
<td>CD15</td>
<td>CD79A</td>
</tr>
<tr>
<td>PAX5 (dim)</td>
<td>PU.1</td>
</tr>
<tr>
<td>CD20</td>
<td>OCT-2</td>
</tr>
<tr>
<td>MUM1</td>
<td>BOB.1</td>
</tr>
<tr>
<td>Fascin</td>
<td>CD10</td>
</tr>
<tr>
<td>LMO2</td>
<td>BCL6</td>
</tr>
<tr>
<td>HGAL</td>
<td>CD45</td>
</tr>
<tr>
<td>CD25</td>
<td>CD43</td>
</tr>
<tr>
<td>Vimentin</td>
<td>EMA</td>
</tr>
<tr>
<td>ALK</td>
<td></td>
</tr>
<tr>
<td>Cytokeratin</td>
<td></td>
</tr>
</tbody>
</table>

Figure 1. Nodular sclerosis subtype of classic Hodgkin lymphoma showing lymph node effacement by cellular nodules surrounded by thick fibrotic bands (A); infiltrate is composed of scattered lacunar cells in the inflammatory background (B). In mixed cellularity subtype of classic Hodgkin lymphoma there is a diffuse infiltrate composed of scattered RS cells in the inflammatory background (C, D). Lymphocyte-rich subtype of CHL showing neoplastic nodule composed almost entirely of small lymphocytes (E); CD30 immunohistochemical staining highlights scattered RS cells. (A-H&E, original magnification ×10; B and D-H&E, original magnification 400; C-H&E, original magnification ×200; E-H&E, original magnification ×100; F-CD30 immunohistochemical stain, original magnification ×200).
Molecular and Cytogenetic Features

Hodgkin/Reed-Sternberg cells likely originate from germinal center B-cells and show monoclonal immunoglobulin heavy-chain gene rearrangements. In some cases, there is "crippling" somatic hypermutation of this gene that would typically lead to the death of the cell by apoptosis; such cells are rescued by oncogenic mutations and/or EBV. Another mechanism contributing to the survival of these cells that are otherwise destined to die is the loss of most B-cell surface proteins, as well a B-cell transcription factors PU.1, OCT-2 and BOB.1 (5, 7, 29, 34-36). This loss of B-cell phenotype is due to epigenetic silencing of B-cell program regulators, promoter hypermethylation, and upregulation of ID2 and NOTCH1, which are transcriptional antagonists (37-40). Given these unique molecular features of neoplastic HRS cells, including loss of B-cell receptor (BCR) which normally leads to apoptosis in mature B cells, they are dependent on multiple alternate pathways for survival. Major genetic alterations in CHL are summarized in Table 2. Constitutive activation of NF-κB and JAK-STAT signaling pathways are the main genetic features of CHL. Canonical and non-canonical NF-κB pathways are activated through several mechanisms, including mutations in negative regulators (TNFAIP3, NFKBIE, NFKB1A) as well as amplifications, chromosomal gains and structural rearrangements that affect gene loci for MAP3K14, REL, and BCL3 and lead to increased activity (41-46). The JAK-STAT pathway is most commonly activated by amplification of JAK2 gene (9p24.1) and mutations and deletions in negative regulators (SOCS1 and PTPN11). Activation leads to increased phosphorylation of STATs, including STAT3, STAT5 and STAT6 and increased transcription of downstream targets (47-52). Other important deregulated pathways in CHL include NOTCH and PI3K-AKT (53). More recent genomic studies showed that cases of refractory CHL show TP53 mutations, as well as mutations of epigenetic regulators EP300 and CREBBP (54-56).

Table 2. Major Genetic Alterations in Classic Hodgkin Lymphoma

<table>
<thead>
<tr>
<th>Pathway</th>
<th>Gene</th>
<th>Alteration</th>
</tr>
</thead>
<tbody>
<tr>
<td>NF-κB</td>
<td>TNFAIP3</td>
<td>Mutation – loss of function</td>
</tr>
<tr>
<td></td>
<td>NFKBIE</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NFKB1A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Amplification</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MAP3K14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>REL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>BCL3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JAK-STAT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>JAK2</td>
<td>(amplification – 9p24.1)</td>
</tr>
<tr>
<td></td>
<td>JAK1</td>
<td>Mutation – gain of function</td>
</tr>
<tr>
<td></td>
<td>JAK3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>STAT3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>STAT5B</td>
<td></td>
</tr>
<tr>
<td></td>
<td>STAT6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mutation – loss of function</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SOCS1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PTPN11</td>
<td></td>
</tr>
<tr>
<td>Immune Escape (evasion)</td>
<td>PDL-1/2</td>
<td>(amplification – 9p24.1)</td>
</tr>
<tr>
<td></td>
<td>Mutation – loss of function</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TNFRSF14</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CD58</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B2M</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CIITA (translocation)</td>
<td></td>
</tr>
<tr>
<td>NOTCH</td>
<td>NOTCH 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>NOTCH 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>FBXW7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SPEN</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PI3K-AKT</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GNA13</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ITPKB</td>
<td></td>
</tr>
</tbody>
</table>

Tumor Microenvironment and Immune Evasion by Reed-Sternberg Cells

Malignant HRS cells are embedded in a dense reactive microenvironment composed of lymphocytes, plasma cells, macrophages, eosinophils,
neutrophils, mast cells, and stromal cells. Through very complex interaction with their microenvironment, mediated by cytokines and chemokines, HRS cells evade immune response, survive and grow (Figure 2) (57-60). The most abundant cells in the microenvironment are CD4+ T cells, mainly T helper 2 (TH2) and T regulatory (Treg) cells that express CCR4 receptor; however, the dominance of TH2 cells has recently been questioned and TH1 cells may be more important. Several chemokines, such as thymus and activation-related chemokine (TARC) and macrophage-derived chemokine (MDC), as well as CCL5 are secreted by HRS cells and attract TH2 and Treg cells via CCR4 receptor (59, 61-64). Macrophages are another very important cell subset in CHL microenvironment and were found to be prognostically relevant. The major cytokines produced by HRS cells that attract macrophages and enhance their function are interferon gamma, CSF1 and CXCL13. Macrophages, on the other hand, secrete macrophage migration inhibitory factor (MIF), which contributes to proliferation of RS cells (59, 65-67).

So-called “immune evasion” of HRS cells occurs through multiple mechanisms. Programmed death protein-1 (PD-1) is expressed in on activated T cells, B cells, macrophages, NK cells, Tregs and follicular T cells. Malignant cells of CHL highly express programmed death ligand-1 (PD-L1) and programmed death ligand-2 (PD-L2). PD-1/PD-L1 binding leads to crosslinking of the antigen-T-cell receptor (TCR) complex with PD-1

![Figure 2. Complex interaction between neoplastic HRS cells and their microenvironment, mediated by cytokines and chemokines. APRIL, a proliferation-inducing ligand; BCL, B lymphocyte chemoattractant; BCMA, B-cell maturation antigen; CC, chemokine (C-C motif); CSF-1, colony stimulating factor-1; CXC, chemokine (C-X-C motif); FASL, Fas ligand; FGF, fibroblast growth factor; Gal-1, galectin-1; IFN-γ, interferon-γ; IL, interleukin; MDC, macrophage-derived chemokine; MIF, macrophage migration inhibitory factor; PDL1, programmed cell death 1 ligand; TARC, thymus and activation-related chemokine; TGF-β, transforming growth factor-β; TH, T helper cell; TNF, tumor necrosis factor; TNFR, tumor necrosis factor receptor; Treg, T regulatory cell; VEGF, vascular endothelial growth factor](image)
which results in attenuation of TCR-associated downstream signaling, decreased cytokine production, and inhibition of T-cell proliferation. In CHL, copy number gains in PD-L1 and PD-L2 (9p24.1) are the main mechanisms for increase in PD-1 protein expression on malignant HRS cells. This leads to T-cell exhaustion (i.e. reduced T-cell activation, suppression of T-cell proliferation and cytokine production) in tumor microenvironment and contributes to immune escape (51, 68-74). Furthermore, amplification of 9p24.1 also results in JAK2 copy gain, increased JAK-STAT signaling, and increase in PD-1 ligand expression (51). Anti-PD-1 blocking antibodies have been successful in prolonging survival of patients with relapsed/refractory CHL (12, 15, 16). Other genetic lesions that contribute to immune evasion of RS cells include translocations of the MHC class II transactivator (CIITA) gene, which result in gene inactivation, and downregulation of HLA class II molecules, as well as increased surface expression of PD-L1/L2 (75). Moreover, inactivating mutations of beta2-microglobulin (B2M) gene result in downregulation of HLA class I molecules (76).

Cytogenetic Studies

Classic Hodgkin lymphoma shows recurrent cytogenetic abnormalities, including copy number changes and translocations. Among the most frequent are amplifications of 9p24.1 locus, affecting JAK2, PD-L1 and PD-L2 genes, as outlined above. Other copy number changes include gains of 2p, 12q, 14q, 16p, 17p, 17 q, 19q, and 20q; and losses of 4q, 6q, 11q, and 13q (45, 77, 78). Translocations involving immunoglobulin loci (IG) are common and can be seen in approximately 20% of cases. The partners were identified in a subset of cases and included REL (2p16), BCL6 (3q27), MYC (8q24), and BCL3/RELB (19q13.2) (79).

Molecular Prognostic Models

Several studies proposed molecular prognostic models in CHL patients with clinically advanced disease by combining expression of multiple genes (80-82). Sanchez-Espiridion et al. (80) applied reverse-transcription polymerase chain reaction (RT-PCR) assay to 282 formalin-fixed paraffin-embedded (FFPE) tissue samples of CHL patients with clinical stage III and IV, as well as stage IIB with bulky disease. They evaluated expression of 30 genes, including genes expressed by malignant cells and microenvironment and integrated best predictor genes into an 11-gene model. The model included four functional pathways – cell cycle, apoptosis, macrophage activation, and interferon regulatory factor 4, and was able to identify a group of high-risk patients with significantly worse 5-year failure free survival (FFS; 44.1% for high-risk vs. 74% for low-risk). Moreover, when combined with clinical stage IV this model identified a group of patients with particularly poor outcome. Scott et al. (81) evaluated expression levels of 259 genes (including genes associated with microenvironment and the cellular processes associated with outcomes in CHL) by NanoString platform on pretreatment FFPE tissue samples from 290 CHL patients with locally extensive or advanced stage disease. Using penalized Cox regression, they created a prognostic model for overall survival (OS) comprising 23 genes. The model separated the patients into low- and high-risk groups (94% vs. 75% 5-year OS) and was validated in an independent CHL cohort. Furthermore, this prognostic model was superior to IPS in the multivariate analysis. Chan et al. (82) constructed an interesting 30 gene model (so-called “RHL30”) using FFPE CHL biopsies taken at disease relapse that predicted outcome post-autologous stem-cell transplantation (ASCT). Gene expression profiling was performed by using NanoString platform and the model included 18 outcome-associated and 12 housekeeping genes and included B-cell, macrophage, RS-cell, neutrophil and natural killer-cell signatures, as well as drug resistance signature. The model identified a group of patients with significantly lower 5-year post-ASCT OS (27.8% for high-risk vs. 85.4% for low-risk) and FFS (23.8% for high-risk vs. 77.5% for low-risk). In summary, these prognostic models are robust and conveniently performed on FFPE tissue samples. However, they
require considerable technical and bioinformatics expertise and are unlikely to become routinely used in the near future.

Immunohistochemical Prognostic Markers

A number of immunohistochemical markers expressed on HRS cells, single or in combination, have been evaluated as prognosticators in CHL. Immunohistochemistry is widely available and relatively inexpensive; however, immunohistochemical studies frequently suffer from poor reproducibility due to differences in tissue fixation and processing, different antibody clones used, and significant interobserver variability (83). More commonly reported immunohistochemical prognostic markers are outlined in Table 3 (30, 84-97).

The most convincing findings appear to be the poorer prognosis associated with BCL2 and T-cell antigen expression by HRS cells (84, 87, 88, 91, 94, 95). Other reported markers associated with decreased survival and refractory disease are MAL and ABCC1 (89, 92). Studies that assessed expression of CD20 showed conflicting results and prognostic significance of CD20 expression in CHL is uncertain (85, 86, 88, 91). Interestingly, studies that assessed prognostic significance of PD-L1 also showed controversial results, including more favorable outcome and poorer prognosis. Ozturk et al. (97) reported poorer prognosis of PD-L1 positive patients. This study also found that overexpression of PD-1 in tumor microenvironment, together with positivity for EBV on RS cells, portends particularly unfavorable prognosis.

Table 3. Immunohistochemical Prognostic Markers Expressed on Hodgkin/Reed-Sternberg Cells in Classic Hodgkin Lymphoma

<table>
<thead>
<tr>
<th>Prognostic marker</th>
<th>Prognosis</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD20</td>
<td>CD20+ - no prognostic significance</td>
<td>Rassidakis et al. (2002)</td>
</tr>
<tr>
<td></td>
<td>CD20+ - decreased OS and FFS</td>
<td>Portlock et al. (2004)</td>
</tr>
<tr>
<td></td>
<td>CD20+ - no prognostic significance</td>
<td>Asano et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>Decreased CD20 expression – associated with refractory disease or early relapse</td>
<td>Canioni et al. (2009)</td>
</tr>
<tr>
<td>BCL2</td>
<td>BCL2+ - decreased FFS</td>
<td>Rassidakis et al. (2002)</td>
</tr>
<tr>
<td></td>
<td>BCL2+ - decreased OS and FFS</td>
<td>Sup et al. (2005)</td>
</tr>
<tr>
<td></td>
<td>BCL2+ - associated with refractory disease or early relapse</td>
<td>Canioni et al. (2009)</td>
</tr>
<tr>
<td></td>
<td>BCL2+ - no prognostic significance</td>
<td>Koh et al. (2013)</td>
</tr>
<tr>
<td>PD-L1</td>
<td>PD-L1+ - increased FFS</td>
<td>Roemer et al. (2018)</td>
</tr>
<tr>
<td></td>
<td>PD-L1+ - associated with advanced disease; when combined with PD-1+ in microenvironment and EBV+ HRS cells – very high-risk disease</td>
<td>Ozturk et al. (2020)</td>
</tr>
<tr>
<td>MHC class I and II</td>
<td>MHC class I+ - no prognostic significance</td>
<td>Roemer et al. (2018)</td>
</tr>
<tr>
<td></td>
<td>MHC class II+ - increased FFS</td>
<td>Diepstra et al. (2007)</td>
</tr>
<tr>
<td>HGAL</td>
<td>HGAL+ - improved OS and FFS</td>
<td>Natkunam et al. (2007)</td>
</tr>
<tr>
<td>MAL</td>
<td>MAL+ - decreased OS and FFS</td>
<td>Hsi et al. (2006)</td>
</tr>
<tr>
<td>ABCC1</td>
<td>ABCC1+ - associated with refractory disease and decreased FFS</td>
<td>Greaves et al. (2013)</td>
</tr>
<tr>
<td>T-cell markers</td>
<td>CD3, CD4, CD8, CD45RO, TIA-1, granzyme B – decreased OS</td>
<td>Asano et al. (2006)</td>
</tr>
<tr>
<td></td>
<td>CD3, CD4, CD8, CD5, CD2, CD7 – decreased OS and FFS</td>
<td>Venkataraman et al. (2013)</td>
</tr>
<tr>
<td></td>
<td>CD2, CD3, CD4, CD5, CD7, TIA-1 – no prognostic significance</td>
<td>Nguyen et al. (2016)</td>
</tr>
</tbody>
</table>

EBV=Epstein-Barr virus; FFS=Failure free survival; OS=Overall survival; HRS=Hodgkin/Reed-Sternberg; *Immunohistochemical markers were correlated with clinical responses and progression-free survival after anti PD-1 therapy (nivolumab); †27 cases in the study expressed different combinations of T-cell markers; ‡50 cases in the study expressed different combinations of T-cell markers, most commonly CD4 and CD2.
Prognostic Markers Associated with Tumor Microenvironment

The prognostic significance of the inflammatory microenvironment in CHL has been a topic of numerous studies. Tumor-associated macrophages and different T-cell subsets have been most studied, but also other cells such as B cells, plasma cells, and mast cells have also been investigated (Table 4) (91, 95, 98-109). Steidl et al. (103) analyzed 130 CHL samples using GEP, which identified a gene signature of tumor-associated macrophages that was associated with poorer prognosis. Numerous immunohistochemical studies have examined prognostic significance of macrophages in CHL microenvironment using CD68 and CD163 antibodies. The results of these studies vary, with some studies showing worse outcome with increased number of macrophages, while others found no impact on survival, suggesting that GEP results from the Steidl et al. (103) study are not consistently reproducible by immunohistochemistry. Guo et al. (107) performed a meta-analysis of 22 studies (2959 patients) that showed high-density of macrophages to be associated with decreased overall and failure-free survival. T-cells in the microenvironment were also found to be important prognostic marker, with increased number of T regulatory cells being associated with better prognosis, while increased number of cytotoxic T cells portends worse prognosis (91, 95, 98-102, 104).

MicroRNA Signature

MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate important biologic processes such as proliferation and differentiation. Furthermore, they can act as oncogens (on-
comirs) and tumor suppressor genes and have an important role in carcinogenesis, including lymphoma development (110-112). Sanchez-Espiridion et al. (113) performed miRNA microarray hybridization to define HRS and microenvironment miRNA signatures on frozen tissue samples from 29 CHL patients with advanced clinical stage. They identified CHL-miRNA signature with 234 differentially expressed miRNAs, a subset of which was prognostic. Quantitative polymerase chain reaction (Q-PCR) was performed to evaluate expression of miRNA associated with clinical outcome in an independent cohort of 168 FFPE CHL samples. Ultimately, a miRNA signature that included MIR21, MIR30E, MIR30D, and MIR92B* stratified patients into two risk groups with significantly different 5-year FFS (35.7% for high-risk vs. 81% for low-risk).

Peripheral Blood Prognostic Markers and Circulating Tumor DNA

Several papers have investigated the role of peripheral blood prognostic markers in CHL; some of these markers are novel and can be used to assess the response to therapy. Poratta et al. (114) reported that peripheral blood lymphocyte/monocyte ratio ≥1.1 was associated with increased OS and PFS. Koh and al. (115) found that patients with absolute neutrophil count/absolute lymphocyte count ≥4.3 had decreased OS. Galectin-1, a carbohydrate-binding protein that plays an important role in immune response and fosters immune escape by tumor, was found to be expressed on HRS cells in CHL (116). Subsequently, Ouyang et al. (117) found that serum levels of galectin-1 are higher in CHL patients that in normal controls. Moreover, higher levels correlated with advanced clinical stage and higher IPS. Hsi et al. (118) analyzed levels of serum soluble chemokines/cytokines produced by HRS cells including TARC, MDC, interleukin-10 (IL-10) and soluble CD163 (sCD163). None of the markers were associated with outcome at diagnosis/baseline. At the time of interim PET study, increased levels of sCD163 were associated with favorable PFS. Furthermore, increased levels of TARC, MDC and IL-10 at the end of therapy were associated with shorter survival, making these markers useful in potentially identifying the patients at higher risk for relapse.

Circulating tumor (ct) DNA analysis by NGS is a particularly attractive approach in CHL and it could become complementary method to tissue biopsy in the near future. There are several possible applications of ctDNA analysis in CHL, including making diagnosis (especially in cases where tumor mass is difficult to biopsy and when biopsy is scant), evaluating response to treatment including minimal residual disease, as well as in prognostication to identify patients who are likely to experience disease relapse (55, 119-122). Several studies showed that mutations detected by analyzing ctDNA mirrored mutations in the corresponding tissue biopsies (55, 119). Higher plasma ctDNA levels at diagnosis were associated with unfavorable clinical characteristics (120). Moreover, in patients who responded well to chemotherapy and had negative PET staging ctDNA became undetectable, while in patients with partial response or refractory disease ctDNA remained detectable (119-122). These findings are important and indicate that ctDNA could be routinely used in disease monitoring after therapy and potentially decrease exposure to radiation from imaging techniques, as well as decrease the need for invasive tissue biopsies.

Epstein-Barr Virus (EBV) – Role in Pathogenesis

Epstein-Barr virus, a member of herpes virus family (a.k.a. Human herpesvirus 4), is an important etiological factor in number of human neoplasms, and is of particular interest in the field of lymphoma pathology (2). Epstein-Barr virus is detected in approximately 20-25% of CHL cases, with viral genomes in monoclonal form. Current “gold standard” for its detection in pathology practice is the EBV-encoded small RNA EBER1. Among the four histologic subtypes, EBV is most consistently and most frequently seen in mixed cellularity subtype (123, 124). The epidemiology of EBV-positive CHL
shows distinct patterns of distribution depending on age, as well as geographic and racial differences. Distribution of EBV-positive CHL cases varies around the world and is generally higher in the resource-poor countries, and more prevalent among Asians and Hispanics, compared to whites and Blacks. As for age, EBV+ cases are common in childhood, uncommon in young adults, and again common among older patients (123, 125). The reasons for these differences are not entirely clear, but are likely multifactorial and related to age of first exposure to EBV, genetic background, and changes in immune system related to disease and aging (so-called immunosenescence) (124, 126). People with a history of infectious mononucleosis have several times increased risk of EBV-positive CHL (127). Also, majority of CHL cases in HIV-positive individuals are EBV-positive (128).

Epstein-Barr virus contributes directly to CHL pathogenesis, via its EBV-encoded proteins, including nuclear antigens (EBNAs), latent membrane proteins (LMP1, LMP2A, and LMP2B), noncoding Epstein-Barr-encoded RNAs (EBER1 and EBER2) as well as miRNAs expressed in infected RS cells. Classic Hodgkin lymphoma is characterized by so-called type II latency pattern, which includes expression of EBNA-1, LMP-1, LMP-2, EBERs, and BART miRNAs (129-131). LMP-1 is similar to constitutively activated CD40 receptor, which leads to induction of JAK/STAT, NF-κB, and PI3K-AKT signaling pathways (132-138). LMP1 also induces PD-L1 expression, contributing to immune evasion (139). EBNA1 contributes to pathogenesis of CHL in several ways, such as inhibiting TGFβ signaling and upregulation of chemokine CCL20 in RS cells, which promotes migration of regulatory T cells (140-142). LMP2 mimics BCR, which allows for B-cell development in the absence of normal BCR signaling. LMP activates cellular pathways required for B-cell survival and can immortalize BCR-negative germinal center B-cells (143-145). The tumor microenvironment in EBV-positive CHL cases is characterized by increased numbers of cytotoxic T cells and significantly higher number of macrophages, compared to EBV-negative cases (98, 102, 146). Prognosis of EBV-positive CHL in elderly population is worse than EBV-negative cases. The choice of treatment for this group of patients are PD-1 inhibitors, which are showing very promising results (147, 148).

Conclusions
Over the past two decades numerous studies have contributed to our understanding of molecular mechanisms of CHL pathogenesis and complex interactions between HRS cells and their inflammatory microenvironment. These discoveries opened many avenues for targeted therapies, some of which are already in routine use in CHL management. The prognosis of CHL is overall favorable with modern therapies, however, up to 30% of patients will experience disease relapse and a small subset is refractory to treatment (12). A number of biological prognostic models and single markers have been proposed to improve risk stratification of CHL patients. Most of these prognostic markers are not routinely implemented at initial diagnosis of CHL, but this will likely change in the future as the goals of CHL therapy, like in other neoplasms, are to achieve sustained remission, prevent relapse, and minimize toxicity. In the era of personalized medicine “one size does not fit all”, and CHL is a prime example of this concept.

Conflict of Interest: The authors declare that they have no conflict of interest.

References


105. Panico L, Tenneriello V, Ronconi F, Lepore M, Cantore N, Dell'Angelo AC, et al. High CD20+ background cells...


134. Eliopoulos AG, Young LS. Activation of the cjun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene. 1998;16(13):1731-42.


